Phosphoproteomics reveals ALK promote cell progress via RAS/JNK pathway in neuroblastoma

Emerging evidence suggests receptor tyrosine kinase ALK as a promising therapeutic target in neuroblastoma. However, clinical trials reveal that a limited proportion of ALK-positive neuroblastoma patients experience clinical benefits from Crizotinib, a clinically approved specific inhibitor of ALK....

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Kai, Lv, Fan, Xu, Guofeng, Zhang, Min, Wu, Yeming, Wu, Zhixiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342791/
https://www.ncbi.nlm.nih.gov/pubmed/27732954
http://dx.doi.org/10.18632/oncotarget.12513

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342791/
https://www.ncbi.nlm.nih.gov/pubmed/27732954
http://dx.doi.org/10.18632/oncotarget.12513

Ejemplares similares